Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Syncona Limited    BACT   GG00B8P59C08


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Syncona : AUTO3 Data Update - ESMO 2020

share with twitter share with LinkedIn share with facebook
09/18/2020 | 07:40am EDT

Nasdaq: AUTL

December 2019

AUTO3 Data Update - ESMO 2020

September 2020

Nasdaq: AUTL


These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements about the safety, therapeutic potential and commercial opportunity of AUTO3 and the future clinical development of AUTO3 including progress, expectations as to the reporting of data, conduct and timing; the Company's plans to develop and commercialize its other product candidates and next generation programs including statements regarding the timing of initiation, completion of enrollment and availability of data from the Company's current preclinical studies and clinical trials; the Company's commercialization, marketing and manufacturing capabilities and strategy; and the impact of the ongoing COVID-19 pandemic on the Company's operations and clinical trials. All statements other than statements of historical fact contained in this presentation, including statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward looking statements include the risks described in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019, as amended, as well as those set forth from time to time in the Company's subsequent SEC filings, available at www.sec.gov. All information contained herein is as of the date of the presentation, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this presentation.

Certain data in this presentation was obtained from various external sources. Such data speak only as of the date referenced in this presentation and neither the Company nor its affiliates, advisors or representatives make any representation as to the accuracy or completeness of that data or undertake to update such data after the date of this presentation. Such data involve risks and uncertainties and are subject to change based on various factors.



  1. Welcome and Introduction: Dr. Christian Itin, Chairman and CEO
  2. Data Review: Dr. Robert Chen, Executive Director, AUTO3 Program Lead
  3. Commercial Opportunity: Brent Rice, Vice President, Chief Commercial Officer
  4. Summary: Dr. Christian Itin, Chairman and CEO
  5. Q&A: Dr. Christian Itin, Andrew Oakley (CFO), Dr. Nushmia Khokhar (Head of Clinical Development), Dr. Robert Chen


Welcome and introduction

Dr. Christian Itin

Chairman and CEO


This is an excerpt of the original content. To continue reading it, access the original document here.


Syncona Ltd. published this content on 18 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 September 2020 11:39:03 UTC

share with twitter share with LinkedIn share with facebook
All news about SYNCONA LIMITED
10/13SYNCONA : Twist Bioscience and Neogene Announce Broad Strategic Partnership for ..
10/07SYNCONA : Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical O..
10/06SYNCONA : Neogene Therapeutics Appoints Former Roche Chairman and Chief Executiv..
09/28SYNCONA : Freeline announces promotion of Romuald Corbau, Ph.D. to Chief Scienti..
09/23SYNCONA : Freeline announces supply agreement for haemophilia B program
09/22SYNCONA : Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, a..
09/18SYNCONA : AUTO3 Data Update - ESMO 2020
09/16SYNCONA : Neogene Therapeutics Raises $110 Million Series A Financing to Develop..
09/11SYNCONA : Gyroscope Therapeutics Announces Appointment of Sean Bohen to the Boar..
09/08SYNCONA : Corporate Presentation
More news
Sales 2020 35,0 M 46,0 M 46,0 M
Net income 2020 - - -
Net cash 2020 767 M 1 009 M 1 009 M
P/E ratio 2020 -
Yield 2020 -
Capitalization 1 642 M 2 157 M 2 159 M
EV / Sales 2020 25,0x
EV / Sales 2021 66,9x
Nbr of Employees -
Free-Float 97,4%
Duration : Period :
Syncona Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNCONA LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 265,33 GBX
Last Close Price 2,47 GBX
Spread / Highest target 11 479%
Spread / Average Target 10 642%
Spread / Lowest Target 9 617%
Melanie Gee Chairman
Thomas Alexander Gavin Henderson Non-Executive Director
Nicholas David Moss Senior Independent Director
Nigel John Keen Non-Executive Director
Ellen R. Strahlman Non-Executive Director
Sector and Competitors